Literature DB >> 961496

New approach to brain tumour chemoradiotherapy with cellular synchronization by colcemid.

N Shitara, T Kohno, K Takakura.   

Abstract

Cellular synchronization using Colcemid as pretreatment for combined chemoradiotherapy was investigated. C6 rat brain tumour was cultured in RPMI medium containing 10(-5)-10(-7) Mol. of Colcemid for 24 hours. The basic cell kinetics were analysed with a Pulse Cytophotometer, which facilitated the analysis of tumour cell cycle phase distribution according to the DNA content. The effect of Colcemid depended on the concentration, and the minimal concentration showing continuous blocking during 48 hours after removal of the drug was 10(-6) Mol. G1 fraction of 2 C DNA content was reduced from 74% to 36%. G2-M phase of 4 C DNA content increased from 9% to 28%. S phase cells increased from 17% to 31%. Polyploid cells in the Tetraploid cell cycle could be recognized. The remaining 36% of cells within the GO + G1 peak of 2 C DNA content were considered to be diploid GO cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 961496     DOI: 10.1007/BF01405940

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  23 in total

1.  Variations in several responses of HeLa cells to x-irradiation during the division cycle.

Authors:  T TERASIMA; L J TOLMACH
Journal:  Biophys J       Date:  1963-01       Impact factor: 4.033

2.  Relative radiosensitivity of different phases in the life cycle of L-P59 mouse fibroblasts and ascites tumor cells.

Authors:  W C DEWEY; R M HUMPHREY
Journal:  Radiat Res       Date:  1962-04       Impact factor: 2.841

3.  A colchicine derivative in therapy of chronic myelocytic leukemia.

Authors:  E M LESSMANN; J E SOKAL
Journal:  JAMA       Date:  1961-03-04       Impact factor: 56.272

4.  Proliferative capacity and DNA content of aging human diploid cells in culture: a cytophotometric and autoradiographic analysis.

Authors:  R Yanishevsky; M L Mendelsohn; B H Mayall; V J Cristofalo
Journal:  J Cell Physiol       Date:  1974-10       Impact factor: 6.384

5.  Cell kinetics of human gliomas.

Authors:  T Hoshino; M Barker; C B Wilson; E B Boldrey; D Fewer
Journal:  J Neurosurg       Date:  1972-07       Impact factor: 5.115

6.  [Cytokinetic effect of bleomycin on mouse Ehrlich carcinoma in vivo. Possibilities of tumor cell synchronization for radiotherapy].

Authors:  J Schumann; W Göhde
Journal:  Strahlentherapie       Date:  1974-03

7.  Synchronisation in vivo: kinetics of a malignant cell system following temporary inhibition of DNA synthesis with hydroxyurea.

Authors:  M F Rajewsky
Journal:  Exp Cell Res       Date:  1970-05       Impact factor: 3.905

8.  [Various radiobiological aspects of "Synchronization therapy in the treatment of tumors"].

Authors:  K R Trott
Journal:  Strahlentherapie       Date:  1971-11

9.  Differentiated rat glial cell strain in tissue culture.

Authors:  P Benda; J Lightbody; G Sato; L Levine; W Sweet
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

10.  LIFE CYCLE ANALYSIS OF MAMMALIAN CELLS. I. A METHOD FOR LOCALIZING METABOLIC EVENTS WITHIN THE LIFE CYCLE, AND ITS APPLICATION TO THE ACTION OF COLCEMIDE AND SUBLETHAL DOSES OF X-IRRADIATION.

Authors:  T T PUCK; J STEFFEN
Journal:  Biophys J       Date:  1963-09       Impact factor: 4.033

View more
  2 in total

1.  Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.

Authors:  M Matsutani; O Nakamura; M Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; K Ueki; Y Tanaka
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

2.  Combination chemoradiotherapy with temozolomide, vincristine, and interferon-β might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.

Authors:  Kenichiro Asano; Toshio Fumoto; Masashi Matsuzaka; Seiko Hasegawa; Naoya Suzuki; Kenichi Akasaka; Kosuke Katayama; Akihisa Kamataki; Akira Kurose; Hiroki Ohkuma
Journal:  BMC Cancer       Date:  2021-07-28       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.